Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Unesbulin · PTC-596

Small molecule · Degrader of BMI1 (polycomb ring finger oncogene) (BMI1) · developed by PTC Therapeutics

Phase 2/3 Most advanced trial
PTCT Developer
2 Registered trials

What is Unesbulin?

Unesbulin is an orally active agent that targets BMI1, a component of polycomb repressive complex 1, in tumor cells and cancer stem cells. It induces hyper-phosphorylation of BMI1, leading to its degradation and a reduction in proliferation of BMI1-expressing tumor cells. It is being studied in high grade glioma, diffuse intrinsic pontine glioma, and leiomyosarcoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PTC-596
Drug type
Small molecule
Targets
BMI1 (polycomb ring finger oncogene) (BMI1)
Mechanism
Degrader of BMI1 (polycomb ring finger oncogene) (BMI1)
Pathways
BMI1-mediated signal transduction, polycomb repressive complex 1 (PRC1) activity
Therapy area
Oncology
Developer
PTC Therapeutics (PTCT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
Z4HZ70S62Q

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05269355 Phase 2/3 Leiomyosarcoma Terminated PTCT
NCT03605550 Phase 1 High Grade Glioma Active not recruiting PTCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diffuse Intrinsic Pontine GliomaHigh Grade GliomaLeiomyosarcoma

More from PTC Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PTCT page.

Follow PTCT, the company behind Unesbulin

See PTCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PTCT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.